Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Kochanny SE, Worden FP, Adkins DR, Lim DW, Bauman JE, Wagner SA, Brisson RJ, Karrison TG, Stadler WM, Vokes EE, Seiwert TY.

Cancer. 2020 Feb 19. doi: 10.1002/cncr.32762. [Epub ahead of print]

PMID:
32073648
2.

Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.

Swiecicki PL, Li P, Bellile E, Stucken C, Malloy K, Shuman A, Spector ME, Chinn S, Casper K, McLean S, Moyer J, Chepeha D, Wolf GT, Prince M, Bradford C, Nyati M, Eisbruch A, Worden FP, Jolly S, Mierzwa M.

Head Neck. 2020 Jan 27. doi: 10.1002/hed.26085. [Epub ahead of print]

PMID:
31989702
3.

A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma.

Swiecicki PL, Durm G, Bellile E, Bhangale A, Brenner JC, Worden FP.

Invest New Drugs. 2020 Jan 24. doi: 10.1007/s10637-020-00898-2. [Epub ahead of print]

PMID:
31981071
4.

Patient-reported financial toxicity and adverse medical consequences in head and neck cancer.

Beeler WH, Bellile EL, Casper KA, Jaworski E, Burger NJ, Malloy KM, Spector ME, Shuman AG, Rosko A, Stucken CL, Chinn SB, Dragovic AF, Chapman CH, Owen D, Jolly S, Bradford CR, Prince MEP, Worden FP, Jagsi R, Mierzwa ML, Swiecicki PL.

Oral Oncol. 2020 Feb;101:104521. doi: 10.1016/j.oraloncology.2019.104521. Epub 2019 Dec 23.

PMID:
31877502
5.

Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.

Rozek LS, Virani S, Bellile EL, Taylor JMG, Sartor MA, Zarins KR, Virani A, Cote C, Worden FP, Mark MEP, McLean SA, Duffy SA, Yoo GH, Saba NF, Shin DM, Kucuk O, Wolf GT.

Nutr Cancer. 2019;71(5):772-780. doi: 10.1080/01635581.2019.1577981. Epub 2019 Mar 12.

PMID:
30862188
6.

Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.

Dacosta Byfield SA, Adejoro O, Copher R, Chatterjee D, Joshi PR, Worden FP.

Adv Ther. 2019 Apr;36(4):896-915. doi: 10.1007/s12325-019-0890-6. Epub 2019 Feb 28.

7.

Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Hawkins PG, Mierzwa ML, Bellile E, Jackson WC, Malloy KM, Chinn SB, Spector ME, Shuman AG, Stucken CL, McLean SA, Bradford CR, Prince ME, Carey TE, Worden FP, Swiecicki PL, Taylor JMG, Wolf GT, Eisbruch A, Casper KA.

Head Neck. 2019 Apr;41(4):857-864. doi: 10.1002/hed.25336. Epub 2019 Feb 18.

PMID:
30775826
8.

Longitudinal patterns of recurrence in patients with adrenocortical carcinoma.

Glenn JA, Else T, Hughes DT, Cohen MS, Jolly S, Giordano TJ, Worden FP, Gauger PG, Hammer GD, Miller BS.

Surgery. 2019 Jan;165(1):186-195. doi: 10.1016/j.surg.2018.04.068. Epub 2018 Oct 19.

PMID:
30343951
9.

Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.

Manohar PM, Beesley LJ, Bellile EL, Worden FP, Avram AM.

Clin Nucl Med. 2018 Sep;43(9):641-647. doi: 10.1097/RLU.0000000000002193.

10.

Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.

Hawkins PG, Lee JY, Mao Y, Li P, Green M, Worden FP, Swiecicki PL, Mierzwa ML, Spector ME, Schipper MJ, Eisbruch A.

Radiother Oncol. 2018 Jan;126(1):68-74. doi: 10.1016/j.radonc.2017.08.002. Epub 2017 Aug 16.

PMID:
28823405
11.

Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck.

Manohar PM, Sapir E, Bellile E, Swiecicki PL, Pearson AT, Prince ME, Shuman AG, Bradford CR, Chepeha DB, Wolf GT, Eisbruch A, Worden FP, Spector ME.

Otolaryngol Head Neck Surg. 2017 Dec;157(6):995-997. doi: 10.1177/0194599817722948. Epub 2017 Aug 15.

PMID:
28809131
12.

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC.

Endocrine. 2017 Aug;57(2):220-225. doi: 10.1007/s12020-017-1359-5. Epub 2017 Jul 6.

PMID:
28685225
13.

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.

J Clin Oncol. 2017 Aug 10;35(23):2692-2699. doi: 10.1200/JCO.2016.71.6472. Epub 2017 Jun 14.

PMID:
28613956
14.

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

Lirov R, Worden FP, Cohen MS.

Drugs. 2017 May;77(7):733-745. doi: 10.1007/s40265-017-0733-1.

15.

Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, Prince ME, Teknos TN, Chepeha DB, Hogikyan ND, McLean SA, Moyer J, Taylor JMG, Worden FP.

JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):355-366. doi: 10.1001/jamaoto.2016.3669.

16.

Buparlisib-and the continued quest for the ideal cure.

Worden FP.

Lancet Oncol. 2017 Mar;18(3):273-274. doi: 10.1016/S1470-2045(17)30027-X. Epub 2017 Jan 26. No abstract available.

PMID:
28131787
17.

Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.

Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, Groen HJ, Gibbs D, Blackman E, Esan M, Brandwein MS, Devarajan K, Bussu F, Chernock R, Chien CY, Cohen MA, Samir EM, Mikio S, D'Souza G, Funchain P, Eng C, Gollin SM, Hong A, Jung YS, Krüger M, Lewis J Jr, Morbini P, Landolfo S, Rittà M, Straetmans J, Szarka K, Tachezy R, Worden FP, Nelson D, Gathere S, Taioli E.

Carcinogenesis. 2017 Feb;38(2):218-229. doi: 10.1093/carcin/bgw203. Epub 2016 Dec 26.

18.

E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.

Spector ME, Sacco AG, Bellile E, Taylor JMG, Jones T, Sun K, Brown WC, Birkeland AC, Bradford CR, Wolf GT, Prince ME, Moyer JS, Malloy K, Swiecicki P, Eisbruch A, McHugh JB, Chepeha DB, Rozek L, Worden FP.

Clin Cancer Res. 2017 Jun 1;23(11):2723-2729. doi: 10.1158/1078-0432.CCR-16-1617. Epub 2016 Nov 21.

19.

Feasibility of Non-invasive Brain Modulation for Management of Pain Related to Chemoradiotherapy in Patients with Advanced Head and Neck Cancer.

Hu XS, Fisher CA, Munz SM, Toback RL, Nascimento TD, Bellile EL, Rozek L, Eisbruch A, Worden FP, Danciu TE, DaSilva AF.

Front Hum Neurosci. 2016 Sep 27;10:466. eCollection 2016.

20.

Predictors of severe long-term toxicity after re-irradiation for head and neck cancer.

Lee JY, Suresh K, Nguyen R, Sapir E, Dow JS, Arnould GS, Worden FP, Spector ME, Prince ME, McLean SA, Shuman AG, Malloy KM, Casper K, Bradford CR, Schipper MJ, Eisbruch A.

Oral Oncol. 2016 Sep;60:32-40. doi: 10.1016/j.oraloncology.2016.06.017. Epub 2016 Jul 5.

PMID:
27531870
21.

Skin cancer of the head and neck with gross or microscopic perineural involvement: Patterns of failure.

Sapir E, Tolpadi A, McHugh J, Samuels SE, Elalfy E, Spector M, Shuman AG, Malloy KM, Prince ME, Bradford CR, Worden FP, Schipper M, Eisbruch A.

Radiother Oncol. 2016 Jul;120(1):81-6. doi: 10.1016/j.radonc.2016.06.011. Epub 2016 Jul 27.

PMID:
27475277
22.

Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma.

Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE.

Mol Cancer Res. 2016 Oct;14(10):941-952. Epub 2016 Jul 15.

23.

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.

Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.

24.

Axitinib in the Treatment of Head and Neck Malignancies.

Swiecicki PL, Spector M, Worden FP.

Curr Clin Pharmacol. 2016;11(2):72-6. Review.

PMID:
27188575
25.

Patient-Reported Toxic Effects-The Dawn of a New Era.

Worden FP.

JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):524-5. doi: 10.1001/jamaoto.2016.0666. No abstract available.

PMID:
27149196
26.

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.

Sacco AG, Worden FP.

Onco Targets Ther. 2016 Apr 4;9:1927-43. doi: 10.2147/OTT.S93720. eCollection 2016. Review.

27.

Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.

Manohar PM, Beesley LJ, Taylor JM, Hesseltine E, Haymart MR, Esfandiari NH, Hanauer DA, Worden FP.

J Thyroid Disord Ther. 2015 Aug;4(3). pii: 188. Epub 2015 Jul 17.

28.

Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer.

Rosko AJ, Spector ME, Griffin GR, Vainshtein JM, Lee J, Bradford CR, Prince ME, Moyer JS, Worden FP, Eisbruch A, Chepeha DB.

Head Neck. 2016 Aug;38(8):1187-93. doi: 10.1002/hed.24348. Epub 2016 Apr 15.

29.

Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center.

Grivas PD, Devata S, Khoriaty R, Boonstra PS, Ruch J, McDonnell K, Hernandez-Aya L, Wilfong J, Smerage J, Ison MG, Eisenberg JNS, Silveira M, Cooney KA, Worden FP.

J Cancer Educ. 2017 Dec;32(4):871-877. doi: 10.1007/s13187-016-1017-2.

PMID:
27055536
30.

Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment.

Spector ME, Chinn SB, Bellile E, Gallagher KK, Kang SY, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Ibrahim M, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2016 Apr;142(4):313-8. doi: 10.1001/jamaoto.2015.3602.

31.

Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches.

Swiecicki PL, Malloy KM, Worden FP.

World J Clin Oncol. 2016 Feb 10;7(1):15-26. doi: 10.5306/wjco.v7.i1.15. Review.

32.

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.

Samuels SE, Tao Y, Lyden T, Haxer M, Spector M, Malloy KM, Prince ME, Bradford CR, Worden FP, Schipper M, Eisbruch A.

Oral Oncol. 2016 Mar;54:68-74. doi: 10.1016/j.oraloncology.2015.12.001. Epub 2016 Jan 6.

33.

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE.

Ann Oncol. 2016 Feb;27(2):318-23. doi: 10.1093/annonc/mdv537. Epub 2015 Nov 23.

34.

A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.

Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP.

Invest New Drugs. 2015 Dec;33(6):1248-56. doi: 10.1007/s10637-015-0293-8. Epub 2015 Oct 10.

PMID:
26453566
35.

Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial.

Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, Feng FY, Eisbruch A, Worden FP, Strath SJ, Jolly S.

Head Neck. 2016 Apr;38 Suppl 1:E1086-96. doi: 10.1002/hed.24162. Epub 2015 Oct 7.

36.

Association Between Multimodality Neck Treatment and Work and Leisure Impairment: A Disease-Specific Measure to Assess Both Impairment and Rehabilitation After Neck Dissection.

Gallagher KK, Sacco AG, Lee JS, Taylor R, Chanowski EJ, Bradford CR, Prince ME, Moyer JS, Wolf GT, Worden FP, Eisbruch A, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2015 Oct;141(10):888-93.

PMID:
26426565
37.

Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.

Wiebel JL, Esfandiari NH, Papaleontiou M, Worden FP, Haymart MR.

Thyroid. 2015 Sep;25(9):1026-32. doi: 10.1089/thy.2015.0062. Epub 2015 Aug 3.

38.

Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer.

Vainshtein JM, Spector ME, Ibrahim M, Bradford CR, Wolf GT, Stenmark MH, Worden FP, McHugh JB, Prince ME, Carey T, Chepeha DB, Eisbruch A.

Head Neck. 2016 Apr;38 Suppl 1:E805-14. doi: 10.1002/hed.24105. Epub 2015 Jul 15.

39.

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.

Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, Lee AW, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito A.

Head Neck. 2016 Apr;38 Suppl 1:E2151-8. doi: 10.1002/hed.24026. Epub 2015 Jul 14. Review.

40.

Trends in imaging after diagnosis of thyroid cancer.

Wiebel JL, Banerjee M, Muenz DG, Worden FP, Haymart MR.

Cancer. 2015 May 1;121(9):1387-94. doi: 10.1002/cncr.29210. Epub 2015 Jan 6.

41.

Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma.

Spector ME, Chinn SB, Bellile E, Gallagher KK, Ibrahim M, Vainshtein J, Chanowski EJ, Walline HM, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey T, Worden FP, Eisbruch A, Chepeha DB.

Head Neck. 2016 Feb;38(2):184-90. doi: 10.1002/hed.23882. Epub 2015 Jun 30.

42.

Conditional survival in patients with thyroid cancer.

Banerjee M, Muenz DG, Worden FP, Wong SL, Haymart MR.

Thyroid. 2014 Dec;24(12):1784-9. doi: 10.1089/thy.2014.0264.

43.

Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio.

Popovtzer A, Normolle D, Worden FP, Prince ME, Chepeha DB, Wolf GT, Bradford CR, Lawrence TS, Eisbruch A.

Transl Oncol. 2014 Aug;7(4):479-83. doi: 10.1016/j.tranon.2014.04.016.

44.

Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor.

Vainshtein J, McHugh JB, Spector ME, Walline HM, Komarck CM, Stenmark MH, Prince ME, Worden FP, Wolf GT, Bradford CR, Chepeha DB, Carey T, Eisbruch A.

Head Neck. 2015 Jan;37(1):8-11. doi: 10.1002/hed.23548. Epub 2014 Apr 15.

45.

Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes.

Singer K, Heiniger N, Thomas I, Worden FP, Menon RK, Chen M.

J Pediatr Endocrinol Metab. 2014 Sep;27(9-10):993-6. doi: 10.1515/jpem-2013-0456.

PMID:
24859505
46.

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.

Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD.

Horm Cancer. 2014 Aug;5(4):232-9. doi: 10.1007/s12672-014-0182-1. Epub 2014 May 22. Erratum in: Horm Cancer. 2014 Dec;5(6):424. Hasseltine, Elizabeth A [corrected to Hesseltine, Elizabeth A].

47.

Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer.

Vainshtein JM, Spector ME, McHugh JB, Wong KK, Walline HM, Byrd SA, Komarck CM, Ibrahim M, Stenmark MH, Prince ME, Bradford CR, Wolf GT, McLean S, Worden FP, Chepeha DB, Carey T, Eisbruch A.

Oral Oncol. 2014 May;50(5):513-9. doi: 10.1016/j.oraloncology.2014.02.001. Epub 2014 Feb 22.

48.

Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):580-8. doi: 10.1016/j.ijrobp.2013.11.246.

49.

Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer.

Vainshtein JM, Spector ME, Stenmark MH, Bradford CR, Wolf GT, Worden FP, Chepeha DB, McHugh JB, Carey T, Wong KK, Eisbruch A.

Oral Oncol. 2014 Mar;50(3):234-9. doi: 10.1016/j.oraloncology.2013.12.003. Epub 2013 Dec 31.

50.

Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma.

Chinn SB, Spector ME, Bellile EL, Rozek LS, Lin T, Teknos TN, Prince ME, Bradford CR, Urba SG, Carey TE, Eisbruch A, Wolf GT, Worden FP, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):134-42. doi: 10.1001/jamaoto.2013.5892.

Supplemental Content

Loading ...
Support Center